[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577380":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":23,"locations":30,"responsibleParty":50,"collaborators":22,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":22,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":22,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":22,"overallStatus":33,"whyStopped":22,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Al-Mustafa University College","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intralesional levofloxacin","EXPERIMENTAL","Intralesional levofloxacin (5 mg\u002Fml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg\u002Fcm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.",[13],"Drug: Levofloxacin 0.5%",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Levofloxacin 0.5%","Intralesional levofloxacin (5 mg\u002Fml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg\u002Fcm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.\n\nThe lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously.",[9],[21],"Tavanic",null,[24],{"name":25,"role":26,"phone":27,"phoneExt":28,"email":29},"Hayder Adnan Fawzi, PhD","CONTACT","07800106177","+ 964","haider-pharm@almustafauniversity.edu.iq",[31],{"facility":32,"status":33,"city":34,"state":22,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Mustansiriyah University","RECRUITING","Baghdad","10047","Iraq","IQ",{"type":39,"coordinates":40},"Point",[41,42],44.40088,33.34058,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":47,"phoneExt":48,"email":49},"Kadhim Ali Kadhim, PhD","7700365655","+964","Pharm.drkaka75@uomustansiriyah.edu.iq",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"SPONSOR_INVESTIGATOR","Hayder Adnan Fawzi","Ass Prof","100577380","phase-2-intralesional-injection-of-levofloxacin-for-the-management-of-cutaneous-leishmaniasis-100577380",false,"NCT06797544","Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis","The Clinical Effect of Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis: Single Arm Open-label Trial","Inclusion Criteria:\n\n* Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis and patients ranging in age from 20 to 75 years old.\n\nExclusion Criteria:\n\n* Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study and patients on prolonged corticosteroid therapy.","ALL","18 Years","80 Years",{"count":65,"type":66},40,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis.\n\nIn an open-label single-arm clinical trial, all patients were given intralesional levofloxacin injections; the patients had cutaneous leishmaniasis lesions. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.\n\nIntralesional levofloxacin (5 mg\u002Fml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg\u002Fcm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment. A fine insulin needle will be used to infiltrate the lesion.",[72],"Cutaneous Leishmaniasis","2025-09-29",{"date":75,"type":76},"2025-09-30","ACTUAL",{"date":78,"type":76},"2025-02-09",{"date":80,"type":66},"2025-11-01",{"name":52,"class":6},1]